IP Library Granted Patent US 12674198
Granted Patent B2
US 12674198 · App. 17/781,726 · Granted Jul 7, 2026

Method and kit for detection of polynucleotide

Inventors: Debojyoti Chakraborty (Delhi, IN); Souvik Maiti (Delhi, IN); Mohammad Azhar (Delhi, IN); Rhythm Phutela (Delhi, IN); Namrata Sharma (Delhi, IN); Dipanjali Sinha (Delhi, IN); Saumya Sharma (Delhi, IN); Arpit Mishra (Delhi, IN); Asgar Hussain Ansari (Delhi, IN)
Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
C12Q1/686C07K14/195C12Q1/6883C12Q1/701
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12674198
App. No.
17/781,726
Granted
Jul 7, 2026
Kind
B2
Abstract

The invention describes a kit for detection of a target polynucleotide using a CRISPR effector system that comprises CAS9 from Francisella novicida , a synthetic sgRNA and a detection scheme based on binding and subsequent enzymatic cleavage of the target polynucleotide. The invention also describes a method for detection of a target polynucleotide using the kit. The kit can be applied to both pathogenic and non-pathogenic polynucleotides and can be used to distinguish polynucleotides different by a single mismatch without the need for sequencing. The kit can also be used for detection of COVID-19. The kit is economical, easy to assemble and provides a robust and rapid readout that can be appropriately adapted for point of care applications.

Claims (23)

1 . A kit for detecting a target polynucleotide, the kit comprising:

a. reverse and forward primers;

b. dNTPS;

c. a PCR buffer;

d. a DNA polymerase;

e. a FnCas9 protein having SEQ ID NO. 2;

f. a single guide RNA; and

g. a CRISPR-CAS9 reaction buffer.

2 . The kit of claim 1 , wherein the single guide RNA has a sequence selected from the group consisting of SEQ ID NOS.: 32, 33, 36, 39, 42, 45, 48, 51-64, 67, 76, 77, 79, and 80.

3 . The kit of claim 1 , wherein the primers are selected from sequences having SEQ ID NOS.: 37, 38, 40, 41, 43, 44, 46, 47, 49, 50, 65, 66, 68, or 69.

4 . The kit of claim 1 , wherein the PCR buffer comprises Recombinase Polymerase Amplification (RPA) Rehydration buffer and Magnesium Acetate.

5 . The kit of claim 1 , wherein the kit further comprises reverse transcriptase.

6 . The kit of claim 1 , wherein the CRISPR-CAS9 reaction buffer comprises one or more of HEPES, KCl, DTT, glycerol and MgCl 2 .

7 . The kit of claim 1 , wherein the primers are labelled with biotin.

8 . The kit of claim 1 , wherein the FnCas9 protein is complexed with a single guide RNA and labelled with a chemical.

9 . The kit of claim 1 , wherein the FnCas9 protein is isolated from Francisella novicida.

10 . The kit of claim 1 , wherein the FnCas9 protein is coupled with a fluorophore tag and has SEQ ID NO: 3.

11 . The kit of claim 1 , wherein the kit further comprises a reaction tube, a dipstick buffer and a paper strip.

12 . The kit of claim 11 , wherein the dipstick buffer is a Tris buffered saline.

13 . The kit of claim 11 , wherein the paper strip is made of a nitrocellulose membrane coated with a biotin-ligand and polyclonal (goat) digoxigenin antibody or polyclonal (rabbit) anti-FITC antibody in gold conjugate.

14 . A FnCas9 ribonucleoprotein complex comprising a Cas9 protein from Francisella novicida having the amino acid sequence as set forth in SEQ ID NO. 2, and a single guide RNA having SEQ ID NO. 79.

15 . The FnCas9 ribonucleoprotein complex of claim 14 , wherein the single guide RNA or its corresponding sequence is selected from the group consisting of SEQ ID NOS.: 5, 6, 8, 9, 11, 12, 14, 15, 17, 18, 19-36, 39, 42, 45, 48, 76, 77, 79, 80.

16 . The FnCas9 ribonucleoprotein complex of claim 14 , wherein the corresponding DNA targeting region in SARS-CoV2 has a sequence as set forth in SEQ ID NOS.: 64, 67.